Souhaitez-vous accéder aux communiqués récents ?

COMMUNIQUÉ DE PRESSE AB SCIENCE OBTIENT UN BREVET JAPONAIS POUR L'UTILISATION DU MASITINIB DANS LE TRAITEMENT DES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES (SEP) JUSQU'EN 2041 IL S'AGIT DU...

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for...

Exton, PA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Updated findings from the Q4 2025 Market Dynamix™: SLE, Pipeline Refresh reveal a maturing and increasingly stratified development landscape, as US...

Austin, TX, USA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “T-Cell Engagers Market Size, Trends and Insights By Product Type (BiTEs...

Weinstein brings more than two decades of experience in life sciences leadership, venture capital, and company buildingProven track record of guiding innovative healthcare organizations from...

2026 soll für BioNTech ein Jahr mit zahlreichen wertrelevanten Meilensteinen (Katalysatoren) werden, unter anderem durch weitere Fortschritte bei Pipeline-Kandidaten, die sich bereits in der späten...

2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026...

The CDMO aseptic filling market size is booming, fueled by rising demand for sterile manufacturing and injectable therapies.

Scenic enters license and research agreement with Ono Pharmaceutical to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutics

ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...